Loading...
XNAS
ENLV
Market cap4mUSD
Oct 08, Last price  
0.28USD
1D
-9.60%
1Q
-95.96%
Jan 2017
-99.96%
IPO
-99.99%
Name

Enlivex Therapeutics Ltd

Chart & performance

D1W1MN
XNAS:ENLV chart
P/E
0.00
P/S
—
EPS
73.40
Div yield, %
—
Shrs. gr., 5y
-24.49%
Rev. gr., 5y
%
Revenues
0
000000002,277,00000000
Net income
1.24b
P
-229,000-1,145,000-7,022,000-15,365,000-16,021,999-5,945,000-4,901,000-9,384,000-11,824,000-14,468,000-31,060,000-29,068,000-15,014,0001,235,528,000
CFO
-10m
L-19.93%
-149,000-865,000-4,409,000-13,249,000-15,486,000-6,352,000-3,161,000-7,041,000-11,007,000-17,542,000-23,953,000-23,523,000-13,008,000-10,416,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.

Key people

Oren Hershkovitz
Chief Executive Officer · since 2019
Shai Novik
Executive Chairman of the Board · since 2014
Dror Mevorach
Founder, Chief Scientific Officer and Medical Officer · since 2009
Shachar Shlosberger
Chief Financial Officer
Baruch Halpert
Director · since 2017
Bernhard Kirschbaum
Director · since 2018
Sangwoo Lee
Director · since 2017
Brian Schwartz
Director · since 2020
Michel Habib
Independent Director · since 2020
Gili Hart
Independent Director · since 2014
Abraham Havron
Independent Director · since 2014
URL
https://www.enlivex.com/
IPO date
Jul 30, 2014
Employees
71
Domiciled in
IL
Incorporated in
IL
Headquarters & legal address
35 AHAD HA'AM STREET
TEL AVIV, TA 6520206
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT